Premium
Response of papillary renal cell carcinoma in a solitary kidney to high dose interleukin therapy
Author(s) -
DINER ERIC K,
LINEHAN MARSTON,
WALTHER MCCLELLAN
Publication year - 2005
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2005.01193.x
Subject(s) - medicine , renal cell carcinoma , papillary renal cell carcinomas , kidney , urology , oncology , pathology
Kidney cancer affects 36 000 Americans annually and is responsible for nearly 12 000 deaths every year in the US. Treatment with interleukin‐2 (IL‐2), the only FDA approved therapy for patients with advanced kidney cancer, is associated with a 10% complete response and a 12% partial response. To date, clear cell renal carcinoma has been the only histological type associated with response to IL‐2‐based therapy. In the current report, we describe a response to IL‐2 therapy in a patient with type I papillary renal carcinoma.